Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 8/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 5/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225959 | 0.94 | CFD (0.40) | CFDKDM4CF2PRSS1CHRM3 | |
| SCHEMBL19225839 | 0.94 | CFD (0.45) | CFDKDM4CF2PRSS1CHRM3 | |
| SCHEMBL19225824 | 0.90 | CFD (0.47) | CFDKDM4CF2PRSS1CHRM3 | |
| SCHEMBL19225818 | 0.86 | CFD (0.42) | CFDKDM4CF2PRSS1CHRM3 | |
| SCHEMBL19225822 | 0.86 | CFD (0.40) | CFDKDM4CF2PRSS1CHRM3 | |
| SCHEMBL19225826 | 0.84 | CFD (0.43) | CFDKDM4CF2PRSS1 | |
| SCHEMBL19225946 | 0.84 | CFD (0.40) | CFDKDM4CF2PRSS1 | |
| SCHEMBL19226032 | 0.83 | CFD (0.44) | CFDKDM4CF2PRSS1 | |
| SCHEMBL19225960 | 0.83 | CFD (0.43) | CFDKDM4CF2PRSS1KMT2A | |
| SCHEMBL15602111 | 0.81 | CFD (0.42) | CFDKDM4CF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |